Skip to main content

01.12.2018 | Case report | Ausgabe 1/2018 Open Access

BMC Nephrology 1/2018

Favorable effect of bortezomib in dense deposit disease associated with monoclonal gammopathy: a case report

BMC Nephrology > Ausgabe 1/2018
Shuma Hirashio, Ayaka Satoh, Takahiro Arima, Kouichi Mandai, Tadasuke Awaya, Kumi Oshima, Shigeo Hara, Takao Masaki



Complement component 3 (C3) glomerulopathy, which includes dense deposit disease (DDD) and C3 glomerulonephritis, is caused by dysregulation of the alternative complement pathway. In most cases, C3 glomerulopathy manifests pathologically with membranoproliferative glomerulonephritis-like features. An association between C3 glomerulopathy and monoclonal gammopathy was recently reported in several cases, raising the possibility that C3 glomerulopathy is the underlying pathological process in monoclonal gammopathy of renal significance.

Case presentation

We herein report a case of monoclonal gammopathy-induced DDD that improved histologically and clinically with chemotherapy including bortezomib. Our case is the first in which treatment response can be linked to the histological response. Potential pathological insights are also discussed.


Rapid and efficient chemotherapy has the potential to limit renal damage in monoclonal gammopathy-associated DDD.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

BMC Nephrology 1/2018 Zur Ausgabe